cisplatin hearing loss children risk

New Study Establishes First Benchmarks for Prevalence and Risk factors for Cisplatin-Induced Hearing Loss in Children

LOS ANGELES, CALIFORNIA — Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this medication, but until now, studies have been too small and too varied to accurately characterize this risk. Last week in The Lancet Child…

Read More
db-020 fast tracked fda

Decibel Therapeutics Announces DB-020 Granted Fast Track Designation by the FDA

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss,…

Read More

Indiana University Cancer Center Researcher Receives $5.7M Grant to Study Chemo-Induced Hearing Loss, Toxicities

INDIANAPOLIS, INDIANA —A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies.  An internationally recognized expert on cancer survivorship, Lois B. Travis, MD, ScD, leads the ongoing study that could lessen…

Read More
hearing loss prevention chemotherapy fennec

Development of Ototoxicity Drug, PEDMARK™, Faces Setback Following FDA Response

RESEARCH TRIANGLE PARK, NORTH CAROLINA — Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that it received a Complete Response Letter (CRL) on August 10, 2020 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity…

Read More
hearing loss prevention chemotherapy fennec

Fennec Announces FDA Filing Acceptance and Priority Review for Ototoxicity Drug, PEDMARK

RESEARCH TRIANGLE PARK, NORTH CAROLINA – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for the company’s New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate). PEDMARK is an investigational drug for the prevention of ototoxicity…

Read More
decibel therapeutics hearing loss treatment

Decibel Therapeutics Publishes Encouraging Results from Phase 1a Clinical Trial of DB-020

BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a development-stage biotechnology company developing novel regenerative therapeutics for hearing loss and balance disorders, announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs. DB-020 is being developed for the prevention of cisplatin-induced hearing…

Read More
chemo hearing loss tinnitus outcomes

Symptoms of Hearing Loss and Tinnitus May Indicate Poor Outcomes in Cancer Survivors

Development of chemotherapy-induced neuropathy (CIN), hearing loss, and/or tinnitus, in cancer survivors may be predictive of increased risk of severe symptom burdens and reduced quality of life (QoL), according to a study published in the European Journal of Oncology Nursing. All three conditions, CIN, hearing loss and tinnitus significantly detracts from patient QoL in numerous…

Read More
hearing loss cisplatin drug sens-401

Study finds Sensorion’s Investigative Drug Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent

MONTPELLIER, FRANCE — French biotech firm, Sensorion, announced the upcoming publication this week in the Journal of Otology & Neurotology of a new study showing oral clinical-stage SENS-401 (the company’s investigative drug) significantly prevented cisplatin-induced hearing loss in preclinical models. Cisplatin, a commonly-used chemotherapy agent to treat various forms of cancer, causes significant levels of…

Read More
hearing loss cancer chemo

Study: Sodium Thiosulfate Treatment Significantly Reduces Chemotherapy-Induced Hearing Loss in Children

LOS ANGELES, CALIFORNIA — According to a new study, investigators at the Children’s Hospital Los Angeles and 37 other Children’s Oncology Group hospitals in the U.S. and Canada have found that sodium thiosulfate helps prevent cisplatin-induced hearing loss in children with cancer. Results of the randomized, controlled, phase 3 study, were published in this month’s…

Read More